BlackRock Advisors’s Coherus Oncology CHRS Stock Holding History

BlackRock Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.32M	Sell	47,024 -30,845	-40%	-$863K	﹤0.01%	1716
2016 Q3	$2.08M	Buy	77,869 +59,626	+327%	+$1.63M	﹤0.01%	1453
2016 Q2	$308K	Buy	18,243 +9,231	+102%	+$173K	﹤0.01%	2380
2016 Q1	$191K	Buy	9,012 +753	+9%	+$12.3K	﹤0.01%	2578
2015 Q4	$190K	Sell	8,259 -4,880	-37%	-$126K	﹤0.01%	2594
2015 Q3	$263K	Buy	13,139 +573	+5%	+$17.4K	﹤0.01%	2571
2015 Q2	$363K	Buy	+12,566	New	+$318K	﹤0.01%	2413

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's CHRS Position: Q4 2016 in Review

BlackRock Advisors reduced its Coherus Oncology (CHRS) stake by 40% in Q4 2016, selling an estimated $863K and leaving 47,024 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

BlackRock Advisors first reported a position in CHRS in Q2 2015 and has held it in 7 quarters since. The position peaked at $2.08M in Q3 2016. 122 funds tracked by Wall St. Rank hold CHRS as of Q4 2016.

BlackRock Advisors held 47,024 shares of Coherus Oncology worth $1.32M as of Q4 2016.
BlackRock Advisors sold 30,845 Coherus Oncology shares in Q4 2016, an estimated $863K.
Coherus Oncology made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1716 holding.
BlackRock Advisors first reported a position in Coherus Oncology in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's Coherus Oncology position peaked at $2.08M in Q3 2016.
122 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.